Concert Pharmaceuticals’ stock rises 80% on a deal with Vertex. Jason Moser analyzes the pharmaceutical landscape and weighs in on The New York Times’ new Twitter strategy.  Plus we dip into the Fool Mailbag and share memories of the late Paul Kangas.

Direct download: Market_Foolery_03_06_2017.mp3
Category:podcast -- posted at: 4:08pm EDT